Table 2.
MINORS rating scale for quality assessment of included studies.
| Study | ① | ② | ③ | ④ | ⑤ | ⑥ | ⑦ | ⑧ | ⑨ | ⑩ | ⑪ | ⑫ | Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Argenziano MG | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 0 | 2 | 2 | 2 | 2 | 21 |
| Cao J | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 2 | 2 | 2 | 2 | 19 |
| Cao Z | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19 |
| Du RH | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 2 | 2 | 20 |
| Ferguson J | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20 |
| Giustino G | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20 |
| Gregoriano C | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 2 | 2 | 2 | 2 | 19 |
| Guan WJ | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18 |
| Guo T | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18 |
| Hong KS | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19 |
| Huang C | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 0 | 2 | 2 | 2 | 2 | 21 |
| Huang R | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20 |
| Israelsen SB | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18 |
| Khamis F | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 2 | 2 | 20 |
| Li C | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20 |
| LI K | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 2 | 2 | 2 | 2 | 19 |
| Li X | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19 |
| Lv Z | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 2 | 2 | 20 |
| Omrani AS | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20 |
| Ortiz-Brizuela E | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18 |
| Pellaud C | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20 |
| Popov GT | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18 |
| Shahriarirad R | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19 |
| Shi S | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 0 | 2 | 2 | 2 | 2 | 21 |
| Suleyman G | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19 |
| Tabata S | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18 |
| Tian S | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20 |
| Turcotte JJ | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19 |
| Wan S | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20 |
| Wang D | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 0 | 2 | 2 | 2 | 2 | 21 |
| Wang W | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 2 | 2 | 20 |
| Wang Y | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 2 | 2 | 2 | 2 | 19 |
| Wang Z | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 0 | 2 | 2 | 2 | 2 | 21 |
| Wei Y | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20 |
| Wu J | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20 |
| Xiong F | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18 |
| Xiong S | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 20 |
| Yang L | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18 |
| Zhang G | 2 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 2 | 2 | 19 |
| Zhang JJ | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18 |
| Zhou J | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 18 |
① A clearly stated aim; ② inclusion of consecutive patients; ③ prospective collection of data; ④ endpoints appropriate to the aim of the study; ⑤ unbiased assessment of the study endpoint; ⑥ follow-up period appropriate to the aim of the study; ⑦ loss to follow up less than 5%; ⑧ prospective calculation of the study size; ⑨ appropriate selection of control group; ⑩ synchronization of control group; ⑪ baseline comparable between groups; and ⑫ appropriately statistical analysis. The global ideal score being 24 for comparative studies.